Mymetics Corp (MYMX)

[Staypositive1]

As we talked earlier. Why do the say that RSV is on hold when we know differently. There are many holes in this Q that out right trying to fool us all.

PAPER

Development of a Virosomal RSV Vaccine Containing

3D-PHAD® Adjuvant: Formulation, Composition,

and Long-Term Stability

J. Lederhofer

1&J. van Lent

2
&F. B h o e l a n

3

&Z. Karneva

3

&A. de Haan

1

&J.C. Wilschut &

T. Stegmann

3

Received: 1 May 2018 /Accepted: 26 June 2018

#The Author(s) 2018

ABSTRACT

Purpose Characterization of virosomes, in late stage preclin-

ical development as vaccines for Respiratory Syncytial Virus

(RSV), with a membrane-incorporated synthetic

monophosphoryl lipid A, 3D-PHAD® adjuvant.

Methods Virosomes were initially formed by contacting a

lipid film containing 3D-PHAD® with viral membranes solu-

bilized with the short chain phospholipid DCPC, followed by

dialysis, later by adding solubilized 3D-PHAD to viral mem-

branes, or to preformed virosomes from DMSO.

Results Virosomes formed from lipid films contained the

membrane glycoproteins G and F, at similar F to G ratios

but lower concentrations than in virus, and the added lipids,

but only a fraction of the 3D-PHAD®. By single particle

tracking (SPT), the virosome size distribution resembled that

seen by cryo-electron microscopy, but dynamic light scattering

showed much larger particles. These differences were caused

by small virosome aggregates. Measured by SPT, virosomes

were stable for 300 days. 3DPHAD ® incorporation in

virosomes could be enhanced by providing the adjuvant from

DCPC solubilized stock, but also by adding DMSO dissolved

adjuvant to pre-formed virosomes. Virosomes with 0.1 mg/

mg of 3D-PHAD®/viral protein from DMSO induced anti-

body titers similar to those by virosomes containing 0.2 mg/

mg of DCPC-solubilized 3D-PHAD®.

Conclusions Stable 3D-PHAD® adjuvanted RSV virosomes

can be formulated


(PDF) Development of a Virosomal RSV Vaccine.... Available from: https://www.researchgate.net/publication/326166555_Development_of_a_Virosomal_RSV_Vaccine_Containing_3D-PHADR_Adjuvant_Formulation_Composition_and_Long-Term_Stability [accessed Aug 13 2018].